Specialty chemical substances organization, Anupam Rasayan India opened its Rs 760-crore initial public offering (IPO) for bidding on March 12. The issue of equity shares will close on March 15. It is completely a fresh issue of equity shares by the company and the net funds will get utilized for debt repayment.
Even though brokerages observe the difficulty is aggressively priced as compared to its peers, all of the broking agency that Businessely spoke to assigned a subscribe score to the issue of equity shares mentioning regular sturdy economic performance, stable relationship with customers, varied and customized product portfolio of the organization.
“The issue of equity shares price was fixed at 553-555 INR per share. “Considering TTM EPS of Rs 5.83 on a post-issue basis, the company is going to list at a P/E of 95.16X with a market-cap of Rs 5,544.5 crore. In comparison, Navin Fluorine is trading at a P/E of 29.6X and PI Industries at 51.4X,” stated Marwadi Shares and Finance.
A big debt compensation responsibility is a key risk, introduced the brokerage
“Considering the growing fancy for lifestyles care & area of expertise chemical substances segment, the enterprise is predicted to do properly submit listing. Moreover, the enterprise has a sturdy financial position and has been positive in cash flow. We are constructive at the stable possibilities of the enterprise,” the brokerage reasoned.
Incorporated in 1984, Anupam Rasayan operates in wonderful commercial enterprise verticals — life sciences-associated area of expertise chemical substances utilized in agrochemicals, personal care and pharmaceuticals; and area of expertise pigment & dyes and polymer additives.
In FY20 and withinside the 9 months ended December 2020, life science-associated area of expertise chemical substances vertical contributed 95.37 % and 93.75 %, respectively, to sales from operations, even as different area of expertise chemical substances contributed 4.63 % and 6.25 % to sales, respectively, all through the equal duration.
Anupam Rasayan published sturdy sales boom of 24.3 % CAGR among FY18 and FY20. Despite the effect of the COVID-19 pandemic, it published sales boom of 45 % for the 9 month duration finishing December 2020 YoY.
Its EBITDA margin increased by way of 397bps all through FY18-20 to at 25.5 % in FY20.
Choice Broking assigned a ‘subscribe for long term’ rating for the issue of equity shares thinking about the sectoral tailwinds and Anupam Rasayan’s varied product applications.
Choice Broking predict a 22.6 % CAGR upward thrust in consolidated topline over FY20-23 to 975.06 INR crore in FY23. EBITDA margin is predicted to settlement by 62bps to 24.9 % in FY23. “While with decrease finance expenses, PAT margin can also additionally increase by 339bps to a stage of 13.4 % in FY23. RoIC and RoE are in all likelihood to increase from 4.1 % and 3.4 % in FY20 to 6.5 % and 7.2 %, respectively, in FY23.”
ICICI Direct believes valuations are at the better aspect for the reason that it’s been dealing with constraints closer to producing free cash flow as a result of better running capital cycle, main to a bloated balance sheet and subdued return ratios.
Angel Broking encouraged subscribing to the issue of equity shares, however highlighted comparable risks.
“(a) The enterprise has incurred notable indebtedness, and an incapacity to conform with repayment should adversely have an effect on business. (b) Experiencing limited cash flows to fulfill required payments on debt and running capital requirements, should adversely effect on operation,” the brokerage detailed.
